Thestrup-Pedersen K, Hammer R, Kaltoft K, Søgaard H, Zachariae H
Department of Dermatology, Marselisborg Hospital, University of Aarhus, Denmark.
Br J Dermatol. 1988 Jun;118(6):811-8. doi: 10.1111/j.1365-2133.1988.tb02600.x.
Eleven patients with mycosis fungoides (MF) were treated with recombinant alpha-interferon (rIFN-alpha 2a2) in combination with etretinate (seven patients) or alone. One patient, who also received etretinate, went into complete remission and remained without signs of MF after 18 months. Six patients experienced partial remission; one of these was treated with rIFN-alpha 2a alone and was clinically in complete remission, but had still a pleomorphic skin infiltrate. Two patients were non-evaluable, and two stopped therapy due to progressive disease. Five patients discontinued therapy due to side-effects although three had partial remission of their disease. Only four patients received 12 months therapy. The study shows that rIFN-alpha 2a in combination with etretinate or alone can induce remission of MF.
11例蕈样肉芽肿（MF）患者接受了重组α干扰素（rIFN-α2a）联合依曲替酯治疗（7例）或单独使用rIFN-α2a治疗。1例同时接受依曲替酯治疗的患者完全缓解，18个月后仍无MF迹象。6例患者部分缓解；其中1例仅接受rIFN-α2a治疗，临床完全缓解，但仍有皮肤多形性浸润。2例患者无法评估，2例因疾病进展停止治疗。5例患者因副作用停止治疗，尽管其中3例疾病部分缓解。仅4例患者接受了12个月的治疗。该研究表明，rIFN-α2a联合依曲替酯或单独使用均可诱导MF缓解。
